Skip to Content

Join the 'Neutropenia Associated with Chemotherapy' group to help and get support from people like you.

Neutropenia Associated with Chemotherapy News

Chemo May Worsen Quality of Life for End-Stage Cancer Patients

Posted 23 Jul 2015 by

THURSDAY, July 23, 2015 – Chemotherapy may worsen quality of life for some cancer patients who are nearing death, a new study finds. "Oncologists may presume there to be no harm in giving dying patients chemotherapy, but these data point to more harm than benefit," study author Dr. Holly Prigerson, from Weill Cornell Medical College in New York City, said in a college news release. The research ...

First Biosimilar Drug Zarxio (filgrastim-sndz) Approved

Posted 8 Mar 2015 by

FRIDAY, March 6, 2015 – The U.S. Food and Drug Administration has approved the first "biosimilar" drug, meaning it is a biologic product that is "highly similar" to an already approved medication. Clinical studies showed Zarxio (filgrastim-sndz) had "no clinically meaningful" difference in safety and effectiveness from the anti-cancer drug Neupogen that was approved in 1991, the FDA said Friday ...

FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz)

Posted 6 Mar 2015 by

March 6, 2015 – The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States. Biological products are generally derived from a living organism. They can come from many sources, including humans, animals, microorganisms or yeast. A biosimilar product is a biological product that is approved based on a showing that it ...

FDA Approves Teva’s Granix (tbo-filgrastim) Injection for Self-Administration

Posted 24 Dec 2014 by

JERUSALEM, December 23, 2014--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. With the approval of this additional administration option, physicians will soon have the flexibility to prescribe Granix for either ...

FDA Approves Tbo-filgrastim for Severe Neutropenia in Certain Cancer Patients

Posted 1 Sep 2012 by

August 29, 2012 – The U.S. Food and Drug Administration today approved Sicor Biotech’s tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils. Tbo-filgrastim is intended for use in adults who have cancers other than blood or bone marrow cancers (non-myeloid malignancies) ...

Ask a Question

Further Information

Related Condition Support Groups


Related Drug Support Groups

Neulasta, Neupogen, filgrastim, pegfilgrastim, tbo-filgrastim, Leukine, Zarxio, sargramostim, Granix